**NM signifies a non meaningful value. A dash signifies the data is not available.
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
8 analysts have expressed a variety of opinions on Bristol-Myers Squibb BMY over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...
In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $50.12.
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...